glp 1 agonist shortage The Multi-Sector Impacts of GLP-1RA Drugs FDA says that the GLP-1
Description
However, given the neutral effect of GLP-1 RAs on surrogate HF outcomes in HFrEF and a potentially increased risk of arrhythmias and HF-related hospitalisations, conducting further large-scale trials in the HFrEF cohort seems complicated
In our present report, we employed a structural approach for the rational design of GLP1R and GIPR dual agonists
2012, doi: 10.1007/s12325-011-0094-1
Note: Market size and forecast figures in this report are generated using Mordor Intelligences proprietary estimation framework, updated with the latest available data and insights as of January 2026
Lets take a look
